Lab21 Plans to Commercialize CES-1 Gene Variants as PGx Test Kits | GenomeWeb

Originally published Aug. 27.

UK-based personalized medicine firm Lab21 will be offering analysis of the CES-1 gene, which has been shown in studies to influence the metabolism of a number of commonly prescribed drugs in people who harbor mutations in this gene.

Lab21 this week said that it has taken a global license from the Medical University of South Carolina's Foundation for Research Development allowing for the detection and analysis of genetic variants of the human carboxylesterase-1 gene.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.